- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02019472
A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis (SIRROUND-H)
September 25, 2017 updated by: Janssen Research & Development, LLC
A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA® Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis
The primary objective is to investigate the efficacy of sirukumab monotherapy compared with adalimumab monotherapy in biologic naïve subjects with active rheumatoid arthritis who are intolerant to methotrexate, who are considered inappropriate for treatment with methotrexate or who are inadequate responders to methotrexate.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, parallel-group, global, multicenter study of subcutaneous (SC) sirukumab monotherapy compared with adalimumab monotherapy in subjects with active rheumatoid arthritis.
Approximately 510 subjects will be randomly assigned in a 1:1:1 ratio to receive treatment with adalimumab 40 mg SC every 2 weeks, sirukumab 100 mg SC every 2 weeks, or 50 mg SC every 4 weeks, with approximately 170 subjects per treatment group.
At Week 16, subjects in all treatment groups who have < 20% improvement from baseline in both swollen and tender joint counts will qualify for early escape.
The expected duration of the study is 68 weeks.
This includes 52 weeks of treatment with study agent and 16 weeks of safety follow-up after the last study agent administration.
The study will end when the last subject completes the last scheduled visit (Week 68 visit or completes the 16 week safety follow-up, whichever is later).
Subject safety will be monitored through the end of the study.
Study Type
Interventional
Enrollment (Actual)
559
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ruse, Bulgaria
-
Sofia, Bulgaria
-
-
-
-
-
Puerto Montt, Chile
-
Temuco, Chile
-
-
-
-
-
Barranquilla, Colombia
-
Bogota, Colombia
-
Bucaramanga, Colombia
-
-
-
-
-
Bad Doberan, Germany
-
Berlin, Germany
-
Köln, Germany
-
Ratingen, Germany
-
Vogelsang-Gommern, Germany
-
-
-
-
-
Debrecen, Hungary
-
Gödöllő, Hungary
-
-
-
-
-
Klaipeda, Lithuania
-
Siauliai, Lithuania
-
Vilnius, Lithuania
-
-
-
-
-
Chihuahua, Mexico
-
Guadalajara, Mexico
-
Jalisco, Mexico
-
Mexicali, Mexico
-
-
-
-
-
Chisinau, Moldova, Republic of
-
-
-
-
-
Bydgoszcz, Poland
-
Bytom, Poland
-
Krakow, Poland
-
Lublin, Poland
-
Nadarzyn, Poland
-
Poznan, Poland
-
Warszawa, Poland
-
Wroclaw, Poland
-
-
-
-
-
Bucharest, Romania
-
Constanta, Romania
-
Ploiesti, Romania
-
-
-
-
-
Arkhangelsk, Russian Federation
-
Kazan, Russian Federation
-
Kemerovo, Russian Federation
-
Kursk, Russian Federation
-
Moscow, Russian Federation
-
Novosibirsk, Russian Federation
-
Petrozavodsk, Russian Federation
-
Ryazan, Russian Federation
-
Saint Petersburg, Russian Federation
-
St Petersburg, Russian Federation
-
St-Petersburg, Russian Federation
-
Tomsk, Russian Federation
-
Tver, Russian Federation
-
Vladimir, Russian Federation
-
Yaroslavl, Russian Federation
-
-
-
-
-
Belgrade, Serbia
-
Novi Sad, Serbia
-
Zemun, Serbia
-
-
-
-
-
Cape Town, South Africa
-
Durban, South Africa
-
Kempton Park, South Africa
-
Stellenbosch, South Africa
-
-
-
-
-
Coruna, Spain
-
Madrid, Spain
-
-
-
-
-
Chernihiv, Ukraine
-
Kryvyi Rih, Ukraine
-
Kyiv, Ukraine
-
Lviv, Ukraine
-
Odessa, Ukraine
-
Poltava, Ukraine
-
Sumy, Ukraine
-
Ternopil, Ukraine
-
Vinnytsia, Ukraine
-
Zaporizhzhia, Ukraine
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
-
Arizona
-
Phoenix, Arizona, United States
-
-
California
-
Arvin, California, United States
-
El Cajon, California, United States
-
Huntington Beach, California, United States
-
Pleasanton, California, United States
-
Thousand Oaks, California, United States
-
Tustin, California, United States
-
Whittier, California, United States
-
-
Delaware
-
Newark, Delaware, United States
-
-
Florida
-
Aventura, Florida, United States
-
Dunedin, Florida, United States
-
Miami, Florida, United States
-
New Port Richey, Florida, United States
-
Palm Harbor, Florida, United States
-
Plantation, Florida, United States
-
Tampa, Florida, United States
-
-
Kansas
-
Kansas City, Kansas, United States
-
-
Kentucky
-
Elizabethtown, Kentucky, United States
-
Paducah, Kentucky, United States
-
-
Maryland
-
Frederick, Maryland, United States
-
Wheaton, Maryland, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
Nevada
-
Las Vegas, Nevada, United States
-
-
North Carolina
-
Salisbury, North Carolina, United States
-
Wilmington, North Carolina, United States
-
-
Ohio
-
Dayton, Ohio, United States
-
-
Oregon
-
Portland, Oregon, United States
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States
-
Wexford, Pennsylvania, United States
-
Wyomissing, Pennsylvania, United States
-
-
Tennessee
-
Jackson, Tennessee, United States
-
Nashville, Tennessee, United States
-
-
Texas
-
Austin, Texas, United States
-
Carrollton, Texas, United States
-
Corpus Christi, Texas, United States
-
Cypress, Texas, United States
-
Lubbock, Texas, United States
-
McKinney, Texas, United States
-
Mesquite, Texas, United States
-
-
Virginia
-
Chesapeake, Virginia, United States
-
-
West Virginia
-
Clarksburg, West Virginia, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have a diagnosis of rheumatoid arthritis (RA) for at least 6 months before screening
- Have moderately to severely active RA with at least 8 of 68 tender joints and 6 of 66 swollen joints, at screening and at baseline
- Have previous or current treatment with methotrexate (MTX) and are considered intolerant to MTX, and/or are considered inappropriate for treatment with MTX, (including MTX-naïve subjects for whom it is inappropriate to administer MTX) and/or an inadequate responder to methotrexate
- Must not have received MTX or any other non-biologic DMARD including but not limited to sulfasalazine, hydroxychloroquine, chloroquine, and bucillamine for at least 2 weeks prior to the first administration of the study agent
- C-reactive protein >= 10.00 mg/L or erythrocyte sedimentation rate >=28 mm/hr at screening
Exclusion Criteria:
- Has Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis
- Has ever received biologic therapy for RA, including but not limited to the following: TNF-alpha inhibitors, tocilizumab, rituximab, anakinra, abatacept
- Has ever used tofacitinib therapy or any other JAK inhibitor
- Has received intra-articular, intramuscular, or IV corticosteroids for RA, including adrenocorticotrophic hormone during the 4 weeks prior to first study agent administration
- Has received leflunomide within 24 months before the first study agent administration and has not undergone a drug elimination procedure, unless the M1 metabolite is measured and is undetectable
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 (adalimumab 40 mg)
Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52.
At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52.
|
SC injections
Other Names:
|
Experimental: Group 2 (sirukumab 100 mg)
Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52.
Subjects may meet the early escape criteria at Week 16 (< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects.
However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
|
SC injections
SC injections
Other Names:
|
Experimental: Group 3 (sirukumab 50 mg)
Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
Between sirukumab injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks through Week 50.
At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive sirukumab 100 mg every 2 weeks through Week 52 and placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
|
SC injections
SC injections
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Disease Activity Index Score 28 (DAS28) Erythrocyte Sedimentation Rate (ESR) at Week 24
Time Frame: Baseline and Week 24
|
The Disease Activity Index Score 28 using ESR [DAS28 (ESR)] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity.
The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities.
The DAS28-ESR is expressed on a score range of "0-10", with the minimum score= 0 (best) to maximum score= 10 (worst).
|
Baseline and Week 24
|
Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 24
Time Frame: Week 24
|
The ACR 50 Response is defined as greater than or equal to (>=) 50 percent (%) improvement in swollen joint count (66 joints) and tender joint count (68 joints) and >= 50% improvement in 3 of following 5 assessments: subject's assessment of pain using Visual Analog Scale (VAS) (0-10 millimeter [mm], 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, [0 mm=no pain to 100 mm=worst possible pain]), physician's global assessment of disease activity using VAS (the scale ranges from 0 to 10, [0=no arthritis activity to 10=extremely active arthritis]), participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI) (the scale ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Disease Activity Index Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) Remission at Week 24
Time Frame: Week 24
|
The Disease Activity Index Score 28 using ESR [DAS28 (ESR)] is a derived score combining tender joints (28 joints), swollen joints (28 joints), ESR, and Patient's Global Assessment of Disease Activity.
The 28 joints evaluated for swelling and tenderness were shoulder, elbow, wrist, MCP1, MCP2, MCP3, MCP4, MCP5, PIP1, PIP2, PIP3, PIP4, PIP5 joints of the upper right and upper left extremities as well as the knee joints of the lower right and lower left extremities.
The DAS28-ESR is expressed on a score range of "0-10", with the minimum score= 0 (best) to maximum score= 10 (worst).
The DAS28 (ESR) remission is defined as a DAS28 (ESR) value of less than 2.6 at a visit.
|
Week 24
|
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24
Time Frame: Week 24
|
The ACR 20 Response is defined as >= 20% improvement in swollen joint count (66 joints) and tender joint count (68 joints) and >=20% improvement in 3 of following 5 assessments: subject's assessment of pain using VAS (0-10 mm, 0 mm=no pain and 10 mm=worst possible pain), subject's global assessment of disease activity by using VAS (the scale ranges from 0 mm to 100 mm, [0 mm=no pain to 100 mm=worst possible pain]), physician's global assessment of disease activity using VAS, subject's assessment of physical function measured by HAQ-DI, defined as a 20-question instrument assessing 8 functional areas.
The derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum CRP.
|
Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 4, 2014
Primary Completion (Actual)
August 17, 2016
Study Completion (Actual)
August 17, 2016
Study Registration Dates
First Submitted
December 18, 2013
First Submitted That Met QC Criteria
December 18, 2013
First Posted (Estimate)
December 24, 2013
Study Record Updates
Last Update Posted (Actual)
October 26, 2017
Last Update Submitted That Met QC Criteria
September 25, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR103111
- CNTO136ARA3005 (Other Identifier: Janssen Research & Development, LLC)
- 2013-001417-32 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arthritis, Rheumatoid
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States